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ABSTRACT
Objective In SLE, smoking increases the burden of 
cutaneous disease and organ damage, and leads to 
premature mortality. However, the effect of smoking on 
disease manifestations and cytokine levels of patients 
with SLE is unclear. This study compared characteristics 
of patients with SLE across smoking status, and 
determined the association of smoking with serum 
cytokine levels.
Method A cross- sectional study of patients with 
SLE (n=99) during a research visit in which smoking 
status was ascertained. Smoking status was compared 
across classification criteria (American College 
of Rheumatology Classification Criteria for SLE 
(ACR97)), disease activity (SLE Disease Activity Index), 
autoantibody levels, accrued damage (Systemic Lupus 
International Collaborating Clinics/ACR Damage Index), 
and circulating concentrations of serum interferon- 
gamma (IFN-γ), interleukin (IL)- 1β, IL- 4, IL- 6, IL- 10, 
IL- 12, IL- 17, B cell- activating factor (BAFF), tumour 
necrosis factor- alpha, transforming growth factor beta 
1 (TGF-β1), macrophage inflammatory protein 1 alpha 
(MIP- 1α), MIP- 1β and monocyte chemoattractant 
protein 1. Linear regression models determined the 
association between smoking and cytokine levels, 
adjusting for age and sex, clinical characteristics (model 
1), and anti- inflammatory (IL- 4, IL- 10 and TGF- β1) and 
regulatory (IL- 1β) cytokines (model 2).
Results Among patients with SLE (97.9% ANA+; mean 
48.48 years old; 86.9% female; mean 10 years of 
disease duration), 35.4% (n=35 of 99) were smoking (an 
average of 7 cigarettes/day for 24 years). Smokers had 
increased odds of prevalent ACR97 malar rash (OR 3.40, 
95% CI 1.23 to 9.34) and mucosal ulcers (OR 3.31, 95% 
CI 1.36 to 8.05). Smokers had more arthritis (OR 3.19, 
95% CI 1.19 to 8.60), migraine (OR 2.82, 95% CI 1.07 to 
7.44), Raynaud’s phenomenon (OR 5.15, 95% CI 1.95 to 
13.56) and increased non- steroidal anti- inflammatory 
drug use (OR 6.88, 95% CI 1.99 to 23.72). Smoking 
associated with 27% increased BAFF levels (95% CI 6% 
to 48%) and 42% decreased IFN-γ levels (95% CI −79% 
to −5%) in model 2.
Conclusion In patients with SLE, smoking independently 
associated with increased BAFF and decreased IFN-γ 
levels, and an increased frequency of arthritis, migraine 
and Raynaud’s phenomenon. Smoking cessation is 
advisable to reduce systemic inflammation, reduce 
disease activity and improve host defence.
INTRODUCTION
SLE is the prototypical autoimmune disease 
characterised by chronic, multisystem inflam-
mation.1 Patients experience an unpredictable 
disease course, which leads to end- stage organ 
damage and premature mortality.1 2 Epide-
miological evidence suggests that smoking 
contributes to the development of ANA and 
Key messages
What is already known about this subject?
 ► Patients with SLE who smoke have more cutaneous 
disease, organ damage and premature mortality, as 
well as reduced medication efficacy. However, the 
effects of smoking on SLE disease activity and cir-
culating cytokine levels are unclear.
What does this study add?
 ► This study shows that patients with SLE who smoke 
have increased odds of arthritis, migraine (lupus 
headache) and secondary Raynaud’s phenomenon, 
which necessitated additional non- steroidal anti- 
inflammatory drug use.
 ► This study showed that while smoking had a broadly 
immunosuppressive effect on cytokine levels in pa-
tients with SLE, it was independently associated with 
increased B cell- activating levels and decreased 
interferon- gamma (IFN-γ) levels.
How might this impact on clinical practice or future 
developments?
 ► Smoking cessation should be advised to reduce sys-
temic inflammation (B cell- activating factor levels) 
and disease activity, that is, arthritis, vasospasm 
(Raynaud’s phenomenon), vasoconstriction (mi-
graine/headache), and global disease activity scores 
[patient/physician visual analogue scale(VAS)], as 
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dsDNA autoantibody formation, which are central to the 
pathogenesis of SLE, particularly lupus nephritis (LN)3; 
and smoking has been linked to an increased risk of 
developing a range of autoimmune diseases, including 
SLE.4–6 In patients with SLE, smoking is linked to cuta-
neous manifestations,7 damage accrual, including the 
earlier onset of end- stage renal disease in those with LN,8 
and premature mortality.9 10 However, the association 
between smoking and SLE disease activity is relatively 
understudied.11
Cigarette smoke exposes the epithelial cells of the 
larynx, bronchi and lung to more than 60 chemical 
carcinogens, which each has the potential to cause DNA 
damage.12 Furthermore, smoking has been shown to 
increase and decrease many proinflammatory and anti- 
inflammatory cytokines in the general population, with13 
and without SARS- CoV- 2 (COVID- 19),14 and in a cohort 
with Sjogren’s syndrome.15 Yet, there are (very) limited 
data on the impact of smoking on serum cytokines in 
patients with SLE, especially in the context of medication 
use and organ damage.5 In SLE, cytokines such as B- cell 
activating factor (BAFF),16 transforming growth factor 
beta 1 (TGF-β1)17 and interferons (IFNs)18 are associated 
with disease activity and severity. Therefore, if smoking 
were to exacerbate abnormal levels of these cytokines, it 
would have implications on the treatment and manage-
ment of SLE. Thus, in this study, we aimed to describe the 
impact of smoking with a range of clinical, serological and 
immunological characteristics in a cohort of patients with 
SLE; and to determine the association between smoking 
and cytokine levels adjusting for age, sex, medication use, 
disease activity and organ damage.
METHOD
This is a cross- sectional study of 99 patients with SLE 
fulfilling the American College of Rheumatology’s 
(ACR) classification criteria for SLE.19 20 Smoking was 
defined as the current consumption of either prefab-
ricated or hand- rolled cigarettes at the research visit. 
Ex- smokers (median 10 years since quitting and a 
median 3.5 pack- year exposure) were counted as non- 
smoking. This was done to align with the stronger asso-
ciation of current smoking rather than ex- smoking 
or non- smoking behaviours with disease activity and 
severity in patients with SLE.21 22
Clinical data including disease activity and labora-
tory results were collected at a research visit, where 
serums taken were stored within 2 hours at −70°C. Cyto-
kine assays were performed for all participants at the 
same time. Serological, immunological and biochem-
istry levels were measured in an accredited laboratory 
on samples taken at the time of research visit. Disease 
activity was recorded using the SLE Disease Activity 
Index- 2K (SLEDAI- 2K).23 We calculated Lupus Low 
Disease Activity State (LLDAS) scores over time,24 and 
presented these data as either >30%, >50%, >70% of 
their time spent in an LLDAS as per Sharma et al.25 
Damage accrual was captured prospectively for each 
participant with the Systemic Lupus International 
Collaborating Clinics/ACR Damage Index for SLE 
(SDI) during a median follow- up of 10 years from 
date of SLE diagnosis through to the research visit.26 
Medication data were collected at the research visit, 
which documented the use of prednisone (oral or 
intravenous methylprednisone), cytostatic agents 
(azathioprine, cyclophosphamide or mycopheno-
late) or immunomodulators (hydroxychloroquine or 
rituximab).
Cytokines (IFN- gamma (IFN-γ), interleukin (IL)- 1β 
(IL- 1β), IL- 4, IL- 6, IL- 10, IL- 12, IL- 17A, BAFF, macro-
phage inflammatory protein 1 alpha (MIP- 1α) 
(patients with SLE only), MIP 1 beta (MIP- 1β) (patients 
with SLE only), monocyte chemoattractant protein 1 
(MCP- 1), tumour necrosis factor- alpha (TNF-α) and 
TGF-β1) were measured in stored (−70°C) serum 
samples by a quantitative sandwich immunoassay 
(Single Analyte ELISArray kit; SuperArray Bioscience 
Corp, Frederick, Maryland, USA). All assays were run 
in duplicate and the results averaged. The manufac-
turer’s recommendations were followed throughout, 
and the same lot was used for each cytokine. For statis-
tical purposes, values below the limit of detection 
(LOD) were replaced by the LOD value.
Statistical methods
Continuous clinical, serological, and immunological vari-
ables are described as a mean±SD or median and IQR 
depending on the data distribution. Continuous data 
were compared across smoking status with t- test, Mann- 
Whitney U test, one- way analysis of variance (ANOVA) 
or Kruskal- Wallis test. Categorical clinical, serological, 
and immunological variables are described as frequency 
(n) and proportion (%), and compared across smoking 
status with logistic regression (presented as an OR with 
95% CIs or a Fisher’s exact test). Cytokine levels were 
described with a geometric mean and 95% CI after under-
going log- transformed to improve normality and then 
back- transformed with Euler’s number.
The associations between smoking and proinflamma-
tory cytokines were determined using Spearman correla-
tion coefficients (Rs) and age- adjusted and sex- adjusted 
linear regression models. Additional multiple regression 
modelling of the association between smoking and cyto-
kine levels included clinical characteristics (age, sex, pred-
nisone use, immunosuppressant use, SLEDAI score and 
SDI score) which are known to influence cytokine levels 
(model 1). Finally, we performed an ad- hoc multiple 
regression model which determined the association of 
smoking with serum BAFF, IFN-γ, IL- 12, IL- 17, TNF-α or 
MIP- 1β, adjusted for model 1 plus anti- inflammatory cyto-
kines (IL- 4, IL- 10, TGF-β1) and the regulatory cytokine 
(IL- 1β). This was to determine whether the minimally 
adjusted association(s) between smoking and cytokine 
levels held after accounting for known lower TGF-β1 
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immunosuppressive effects of smoking on key regulatory 
and anti- inflammatory cytokines IL- 1β, IL- 4 and IL- 10.27–30
RESULTS
Clinical characteristics of patients with SLE at the research 
visit compared across smoking status
At the research visit, patients with SLE (97.9% ANA+) 
were on average 48 years old, 86.9% female and had been 
followed up for an average of 10 years. At the research 
visit, 35.4% (n=35 of 99) were currently smoking (average 
of 7 cigarettes per day for 24 years) (table 1). Within non- 
smokers, 39.1% (n=25 of 64) were ex- smokers (average of 
9 cigarettes per day for 15 years), with cessation occurring 
on average 10 years prior to the research visit. Current 
smokers had a significantly higher pack- year smoking 
exposure than ex- smokers (9 vs 3.5 pack- years, p=0.003). 
Within current smokers, 57.1% (n=20 of 35) had a <10 
pack- year smoking exposure. A total of 34.3% (n=12 of 
35) had a 10–20 pack- year smoking exposure, and 8.6% 
(n=3 of 35) had a ≥20 pack- year smoking exposure. 
Current and non- smokers had an equivalent burden of 
comorbid vascular, pulmonary, malignancy and metabolic 
pathology, as well as accrued damage (SDI >0) and total 
SDI scores. However, patients with any smoking exposure 
(current and/or ex- smokers) had higher accrued damage 
(69.0% vs 46.3%; OR 2.57, 95% CI 1.12 to 5.89; p=0.025) 
and malignancy (20.7% vs 4.9%; OR 5.09, 95% CI 1.07 to 
24.13; p=0.041).
There was a higher cumulative prevalence of malar 
rash (OR 3.40, 95% CI 1.23 to 9.34; p=0.018), mucosal 
ulcers (OR 3.31, 95% CI 1.36 to 8.05; p=0.008), arthritis 
(OR 3.19, 95% CI 1.19 to 8.60; p=0.022) and Raynaud’s 
phenomenon (OR 5.15, 95% CI 1.95 to 13.56; p=0.001) 
in current smokers (online supplemental table 1). 
SLEDAI- 2K scores were equivalent across smoking status, 
although current smokers had increased odds of migraine 
(OR 2.82, 95% CI 1.07 to 7.44; p=0.037), with similar 
representation of other SLEDAI features. Both patient 
(4 vs 2, p=0.003) and physician (3 vs 2, p=0.046) global 
disease activity (GDA) visual analogue scale (VAS) scores 
were however higher. The increased odds of Raynaud’s 
phenomenon in current smokers were higher in male 
patients (data not shown). Laboratory findings demon-
strated that current and non- smokers had similar immu-
nological disease activity, including ANA and anti- dsDNA 
seropositivity, hypocomplementemia and cytopenias. 
However, current smokers had higher levels of haemo-
globin (13.06 vs 12.99, p=0.036), mean corpuscular 
volume (MCV) (91.91 vs 88.52, p=0.014) and B cells (0.14 
vs 0.08, p=0.037), with lower ApoA 1 lipoprotein levels 
(1.48 vs 1.61, p=0.039). Smoking was not associated with 
anti- dsDNA titres (ELIA Rs −0.03, p=0.776), complement 
protein (C3) (Rs −0.07, p=0.480) or C4 (Rs 0.14, p=0.174) 
(online supplemental table 4).
The management of SLE required non- steroidal anti- 
inflammatories in 15.2% (n=15 of 99), prednisone in 
50.5% (50 of 99), hydroxychloroquine in 58.6% (n=58 
of 99) and immunosuppression in 36.4% (n=36 of 99). 
Medication requirement for SLE was similar across 
smoking status with the exception of additional non- 
steroidal anti- inflammatory drug (NSAID) requirement 
in smokers (OR 6.88, 95% CI 1.99 to 23.72; p=0.002). 
Medication requirement for comorbid conditions was 
equivalent across smoking status (online supplemental 
table 5).
Comparison of cytokine levels between patients with SLE and 
healthy controls
Compared with controls, patients with SLE had higher 
average levels of BAFF (1.74 vs 0.94 ng/mL, p<0.001) 
and MCP- 1 (137.42 vs 98.22 pg/mL, p=0.028), while 
having lower levels of IL- 1β (26.85 vs 67.86, p<0.001) 
and TGF-β1 (581.74 vs 733.39, p=0.018). Within 
patients with SLE, smokers had higher average levels 
of BAFF (2.01 vs 1.61 ng/mL, p=0.034), yet lower 
levels of IFN-γ (39.37 vs 82.98 pg/mL, p=0.002), TNF-α 
(35.41 vs 58.37 pg/mL, p=0.024) and MIP- 1β (509.26 
vs 625.65 pg/mL, p=0.022). Compared with controls, 
patients with SLE who smoked had higher levels of 
BAFF (2.01 vs 0.94 ng/mL, p<0.001) and MCP- 1 (118.9 
vs 98.22 pg/mL, p=0.031), and lower IL- 1β (21.85 vs 
67.86 pg/mL, p=0.006) but equivalent IFN-γ levels 
(39.37 vs 53.88, p=0.064) (table 2).
Association of smoking with cytokine levels
Smoking correlated with increased BAFF levels (Rs 0.20, 
p=0.043) leading to 27% and 28% increased BAFF levels 
after adjusting for age and sex (95% CI 3% to 57%; 
p=0.023) and clinical covariates (model 1) (95% CI 5% to 
57%, p=0.015), respectively. Smoking inversely correlated 
with IFN-γ levels (Rs −0.32, p=0.001) and a 55% decrease 
IFN-γ in both the age- adjusted and sex- adjusted (95% CI 
−71% to −27%, p=0.001) and clinical covariate adjusted 
models (95% CI −72% to −28%; p=0.001). Smoking 
inversely associated with TNF-α and MIP- 1β levels in 
the univariate, age- adjusted and sex- adjusted model, 
and model 1. Smoking inversely correlated with IL- 4 
(Rs −0.25, p=0.015), but was not in the adjusted models. 
Smoking associated with reduced levels of IL- 1β in the 
age- adjusted and sex- adjusted model only. Smoking asso-
ciated with decreased IL- 12 and IL- 17 in the age- adjusted 
and sex- adjusted model and model 1, but not model 2 
(table 3).
Analysis further adjusting for anti-inflammatory or regulatory 
cytokines
With further adjustment for anti- inflammatory cytokines 
(IL- 4, IL- 10 and TGF-β1) and regulatory cytokine IL- 1β 
(model 2), smoking increased BAFF levels by 27% (95% 
CI 6% to 48%; p=0.014) and decreased IFN-γ levels by 42% 
(95% CI −79% to −5%; p=0.026); however, smoking no 
longer associated with changes in IL- 12, IL- 17, TNF-α or 
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Table 1 Characteristics of patients with SLE at the research visit compared across smoking status
Overall Current smoker
Not currently 
smoking OR (95% CI) P value
Participants, n 99 35 64
Age, mean±SD 48.48±15.75 46.91±13.49 49.33±16.89 – 0.941
Male, n (%) 13 (13.1) 7 (20.0) 6 (9.4) – 0.135
Female, n (%) 86 (86.9) 28 (80.0) 58 (90.6) –
Years of follow- up, 
median (IQR)
10.42 (5.08–17.67) 10.42 (5.08–16.75) 10.46 (4.92–17.67) – 0.941
Smoking details
Ex- smoker, n (%) 25 (39.1) – 25 (39.1) –
Cigarettes per day, 
median (IQR)
7 (3–10) 7 (3–10) 9 (4–10) – 0.428
Years of consistent daily 
smoking, median (IQR)
20.0 (13.0–28.00) 24.0 (18.0–30.0) 15.0 (5.0–23.0) – 0.064
Pack- years, median 
(IQR)
5.0 (3.0–12.25) 9.00 (3.75–14.00) 3.5 (2.0–5.0) – 0.003
Years since quit 
smoking, median (IQR)
10 (6–18) – 10 (6–18) – –
Cumulative ACR97 classification criteria
Cumulative ACR97 
items, median (IQR)
5 (4–7) 6 (4–7) 5 (4–7) – 0.651
Positive ANA, n (%) 97 (97.9) 35 (100.0) 62 (96.9) – –
Mucosal- cutaneous 
features*, n (%)
95 (96.0) 34 (97.1) 61 (95.3) 1.67 (0.17 to 16.71) 0.662
Malar rash, n (%) 66 (67.3) 29 (82.9) 37 (58.7) 3.40 (1.23 to 9.34) 0.018
Photosensitivity, n (%) 59 (60.2) 23 (65.7) 36 (57.1) 1.44 (0.61 to 3.39) 0.407
Discoid lupus, n (%) 42 (42.9) 18 (51.4) 24 (38.1) 1.72 (0.75 to 3.97) 0.203
Mucosal ulcers, n (%) 31 (31.6) 17 (48.6) 14 (22.2) 3.31 (1.36 to 8.05) 0.008
Disease activity at the research visit (SLEDAI)
Clinical disease activity, 
n (%)
84 (84.8) 28 (28.0) 56 (56.5) 0.57 (0.19 to 1.74) 0.324
Migraine, n (%) 22 (22.2) 12 (12.3) 10 (10.6) 2.82 (1.07 to 7.44) 0.037
Arthritis, n (%) 21 (21.2) 12 (34.3) 9 (14.1) 3.19 (1.19 to 8.60) 0.022
Clinical SLEDAI score, 
median (IQR)
6 (2–12) 6 (2–14) 6 (2–10) – 0.981
Total SLEDAI score, 
median (IQR)
8 (2–14) 8 (4–16) 8 (2–11) – 0.998
Patient GDA VAS, 
median (IQR)
3 (1–5) 4 (3–6) 2 (1–5) – 0.003
Physician GDA VAS, 
median (IQR)
2 (1–4) 3 (2–4) 2 (1–3) – 0.046
LDAS- 50 35 (37.2) 13 (37.1) 22 (37.3) 0.99 (0.42 to 2.36) 0.989
LDAS- 30 62 (66.0) 21 (60.0) 41 (69.5) 0.66 (0.28 to 1.58) 0.349




25 (25.3) 16 (16.7) 9 (9.1) 5.15 (1.95 to 13.56) 0.001
Medication requirement
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DISCUSSION
This cross- sectional cohort study demonstrates that 
in patients with SLE, current smoking associates with 
increased BAFF levels and decreased IFN-γ levels. This 
was on a background of current smokers having increased 
joint manifestations necessitating higher NSAID usage, 
migraine, Raynaud’s phenomenon and increased GDA 
scores. Current smokers had accrued more malar rash and 
mucosal ulcers over time (ACR97), but not skin damage 
(OR 3.82, p=0281). Having ever smoked was associated 
with increased odds of organ damage and cancer develop-
ment. However, current smokers and non- smokers were 
similar with respect to the remaining ACR97 classifica-
tion criteria items and scores, cross- sectional SLEDAI- 2K 
scores, damage accrual (SDI >0, 59.6%), comorbidity and 
other medication requirement.
The harmful effects of cigarette smoking are well estab-
lished in the general population, and the more recent 
phenomenon of smoking e- cigarettes (vaping) is gradually 
being shown to equally so.31 The 35.4% of patients with 
SLE smoking and the 25 (39.1%) ex- smokers aligned with 
Norwegian national survey data on smoking prevalence 
and cessation at the time of the study.32 Compared with 
other studies of patients with SLE, smoking prevalence 
Overall Current smoker
Not currently 
smoking OR (95% CI) P value
Prednisone dose (mg), 
median (IQR)
5.00 (5.00–7.50) 5.00 (5.00–7.50) 5.00 (5.00–10.00) 0.898
Non- steroidal anti- 
inflammatories, n (%)
15 (15.2) 11 (31.4) 4 (6.3) 6.88 (1.99 to 23.72) 0.002
Hydroxychloroquine, n 
(%)
58 (58.6) 19 (54.3) 39 (60.9) 0.76 (0.33 to 1.75) 0.521
Immunosuppressants, 
n (%)
36 (36.4) 13 (37.1) 23 (35.9) 1.05 (0.45 to 2.48) 0.905
Comorbidity
Metabolic disorder, n (%) 61 (61.2) 20 (57.1) 41 (68.3) 0.62 (0.26 to 1.46) 0.274
Dyslipidaemia, n (%) 49 (49.1) 15 (42.9) 34 (57.6) 0.55 (0.24 to 1.28) 0.168
BMI ≥30, n (%) 12 (12.9) 3 (8.6) 9 (15.5) 0.51 (0.13 to 2.03) 0.340
Diabetes, n (%) 3 (3.2) 3 (8.6) 0 (0.0) – –
Hypertension, n (%) 49 (49.6) 15 (42.9) 34 (56.7) 0.57 (0.25 to 1.33) 0.196
Cardiovascular disease, 
n (%)
31 (31.1) 12 (34.3) 19 (29.7) 1.24 (0.51 to 2.98) 0.637
Heart attack, n (%) 13 (13.8) 6 (17.1) 7 (11.9) 1.54 (0.47 to 5.01) 0.476
Thromboembolic 
disease, n (%)
13 (13.8) 4 (11.4) 9 (15.3) 0.72 (0.20 to 2.53) 0.605
Stroke, n (%) 5 (5.3) 2 (5.7) 3 (5.1) 1.13 (0.18 to 7.13) 0.895
Cancer, n (%) 11 (11.7) 1 (2.9) 10 (16.9) 0.14 (0.02 to 1.18) 0.071
Pulmonary diseases†, 
n (%)
13 (13.1) 6 (17.1) 7 (10.9) 1.69 (0.52 to 5.48) 0.386
Damage accrual (SDI 
>0), n (%)
59 (59.6) 24 (68.6) 35 (54.7) 1.81 (0.76 to 4.30) 0.181
Total SDI score, median 
(IQR)
2.00 (1.00–3.00) 1.00 (1.00–2.00) 2.00 (2.00–4.00) 0.140
Skin damage, n (%) 3 (3.0) 2 (5.7) 1 (1.6) 3.82 (0.33 to 43.68) 0.281
Pulmonary damage, n 
(%)
7 (7.1) 4 (11.4) 3 (4.7) 2.62 (0.55 to 12.46) 0.225
Malignancy damage, n 
(%)
14 (14.1) 3 (8.6) 11 (17.2) 0.45 (0.12 to 1.74) 0.249
Bolded findings are significantly different across current and those not currently smoking.
*Also includes alopecia.
†Pulmonary diseases include fibrotic and obstructive diseases (asthma n=6).
ACR97, American College of Rheumatology Classification Criteria for SLE; BMI, body mass index (kg/m2); GDA, global disease activity; 
LDAS- 50, Low Disease Activity State- 50; SDI, Systemic Lupus International Collaborating Clinics/ACR Damage Index; SLEDAI, SLE Disease 
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was equivalent to studies based in the USA (32% current 
smokers) and Denmark (51% ever- smoked), but higher 
than in Canada (14% current smokers) and Brazil (8% 
current smokers).7 10 11 21 Similarly, smoking intensity 
(cigarettes per day and pack- years) in our cohort was 
equivalent to those who reported it.7 11 21 Despite the 
Norwegian effort to promote smoking cessation, the prev-
alence of smoking is currently around 20%, and it is not 
expected to fall below 10% until 2029,32 which indicates 
that an opportunity still exists for clinicians to encourage 
smoking cessation in their patients.
Our cohort was similar to other studies about the 
impact of smoking on SLE, with respect to participants’ 
age (mean 48 years old),21 disease duration (an average 
of 10 years)21 and sex distribution.7 11 21 22 The higher 
odds of prevalent (ACR97) mucosal ulcers in our cohort 
add to the established link between current smoking and 
(active) mucocutaneous features in SLE.21 In spite of the 
small numbers, we showed a signal of more skin damage 
in current smokers (OR 3.82; p>0.05), although similar 
for the over- representation of cumulative cutaneous 
features in smokers. Our findings differed to others who 
showed that having ever smoked7 or having had a >20 
pack- year history11 increased the odds of discoid lesions 
and photosensitivity. The increased odds of mucosal 
rather than discoid lesions and photosensitivity may result 
from differences in the ultraviolet (UV) light exposure at 
each research setting,33 with Tromso (Northern Norway) 
having lower peak UV (~4) compared with the Cana-
dian and Danish studies (~6 UV index).7 11 We showed 
that having ever smoked rather than current smoking 
alone resulted in proportionally more damage accrual 
and malignancy. This aligned with Bourré-Tessier et al 
who reported that smoking associated with lung cancer 
in patients with SLE.7 Taken together, patients with SLE 
should be advised to cease smoking to reduce the odds 
of mucocutaneous disease flares, damage accrual and 
cancer development.
Similar to other cross- sectional studies, smoking exhib-
ited little influence on total SLEDAI score, rather we 
showed increased odds of arthritis, migraine and vasculitis 
(Raynaud’s phenomenon).11 21 In contrast, other studies 
showed that smoking increased average SLEDAI scores,21 
increased cutaneous- SLE disease activity,34 and either 
slowed or prevented the reduction of SLEDAI scores 
after treatment with belimumab.35 Herein, the increased 
odds of arthritis in patients with SLE who smoked 
contradicted the inverse association between a smoking 
history of >20 pack- years and with non- erosive arthritis 
(OR=0.45) reported by Leffers et al.11 However, in the 
context of the lower IFN-γ levels shown herein, our data 
align with murine models, which showed that smoking 
can cause a collagen- induced arthritis.36 37 Patients with 
SLE who smoked also had more migraine, headache and 
Raynaud’s phenomenon (disproportionately affecting 
men). This fits with the increased frequency of headache 
and vasculitis in active smokers, and the increased odds 
of neurological disorders in those with smoking history 
of >20 pack- years reported elsewhere.10 11 21 38 Patients 
with SLE who smoked also had increased patient and 
physician GDA scores (0–10 mm VAS). Yet, similar to 
Golder et al, we found that smoking status (current or 
ex- smoking) had no influence on LLDAS- 30, LLDAS- 50 
or LLDAS- 70 scores (all p>0.30).39 Thus, in patients with 
SLE, we suspect that the harmful effects of smoking to 
health, systemic inflammation and disease activity are not 
entirely captured by the SLEDAI- 2K,23 which may mean 
that the impact of smoking is potentially obscured in 
current treat- to- target indices.39
For similar medication profiles, current smokers 
trended towards a reduction in the prevalence (OR 0.52, 
p=0.125) and severity of the typical cytopenias seen in 
SLE, and current smokers had increased levels of haemo-
globin and MCV.40 41 This reflects the increased systemic 
inflammatory state brought about by smoking- induced 
damage to the lungs and circulation of smoking by- prod-
ucts throughout the body.40 41 In spite of the increased 
systemic inflammatory state, smoking did not influence 
the proportion with active hypocomplementemia and 
autoantibody production, which is consistent with the 
literature.4 10 42 43 Thus, clinicians should advise their 
patients that smoking causes acute systemic damage to 
the body, beyond what is captured within the routine clin-
ical assessment (SLEDAI- 2K) or target- to- treat indices of 
SLE.
The increased (27%) serum BAFF levels in patients with 
SLE who smoked confirmed the 8.7% and 24% increase 
seen in (ANA−/ANA+) smokers in the Nurse’s Health 
Study (n=1177), respectively.5 Smoking has been shown 
to increase serum BAFF levels in the absence of autoim-
mune disease.5 44 The overexpression of BAFF in SLE is 
hypothesised to be driven by localised inflammation or 
B cell activation resulting from inherent immune dysreg-
ulation in SLE.30 45 BAFF levels have also been associated 
with disease activity46 and organ damage47 48 in some but 
not all cohort studies.45 Yet, the failure of monoclonal 
anti- BAFF therapy to dampen disease activity49 suggests 
that aberrant BAFF production is a feature rather than 
a direct cause of lupus disease activity.45 Furthermore, 
smoking has been shown to reduce the efficacy of belim-
umab (BAFF inhibition)35 and antimalarial agents in the 
management of SLE.50 Taken together, the independent 
association between smoking and BAFF levels, on a back-
ground of increased physician GDA score arthritis and 
vasculopathies, suggests that smoking cessation should be 
a priority in the management of SLE to reduce systemic 
inflammation and disease activity, which would help to 
reduce serum BAFF levels.30
Innate antiviral immune competence is a major func-
tion of many type I IFNs, which along with IL- 12, IL- 15 
and IL- 18, can induce type II IFN (IFN-γ) production.51 
Dysregulation of type I IFN, and potentially type II 
IFN (IFN-γ), can lead to uncontrolled virus replication 
coupled with uncontrolled inflammation which causes 
tissue damage.51 IFN-γ in inflammatory and autoimmune 
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which often moderate disease severity, and maintains anti-
viral and microbial defences, among other features.52–56 
We showed increased IFN-γ levels in non- smoking 
patients with SLE compared with healthy controls (82.98 
vs 53.88 pg/mL, p<0.001).18 57 However, patients with 
SLE who smoked had IFN-γ levels similar to and trending 
lower than those of healthy controls (39.37 vs 53.88 pg/
mL, p=0.064). The suppression of IFN-γ levels within 
patients with SLE who smoked (model 2) aligns with the 
literature about smoking- induced suppression of type I 
and II IFN cytokines.58–62 With respect to IFNs, smoking 
can cause phosphorylation- dependent downregulation 
of IFN- 1A receptor (IFN- 1AR) by reactive oxygen species 
(ROS),63 which, although unproven as yet, may result 
from exposure to the major phenolic components of 
cigarette tar, hydroquinone and catechol.27 Additionally, 
the phosphorylation- dependent downregulation of IFN- 
1AR by ROS was ameliorated by the antioxidant N- ace-
tylcysteine (NAC).63 Interestingly, in patients with SLE, 
disease activity was shown to improve within 1 month of 
administration of NAC (2.4–4.8 g/day),64 which suggests 
that perhaps, NAC supplementation may be beneficial in 
patients with SLE,65 especially for those struggling with 
smoking cessation.66 Nicotine has been recently cited as 
having beneficial proinflammatory and anti- inflammatory 
effects67; and pertinent to SLE, nicotine was shown to 
augment TGF-β levels and increase expression of FoxP3 
in mice.68 However, in our study, TGF-β1 levels were lowest 
in patients with SLE who smoked. Thus, while nicotine 
replacement therapy has its use in smoking cessation, 
its psychoactive properties (addictive), vasoconstrictive 
properties (perhaps responsible for the increased odds of 
headache and Raynaud’s phenomenon seen herein) and 
the significantly reduced levels of TGF-β1 levels of current 
smokers make its potential use as an immune modulator 
unlikely.69 Ultimately, the ability of NAC supplementation 
and nicotine to influence systemic and immune- mediated 
inflammation requires further study in patients with SLE. 
The clinical phenotype of patients with SLE who smoked 
aligns with murine model data, in which, the absence of 
IFN-γ had a significant reduction in serum immunoglob-
ulins, ANA and anti- dsDNA seropositivity, renal immune 
deposits and proteinuria.38 Similarly, in murine models 
of collagen- induced arthritis, IFN-γ was protective against 
arthritis by inhibiting the development of Th17 cyto-
kines.36 37 Taken together, smoking in SLE depletes IFN-γ 
to levels similar to or beyond those of healthy controls, 
with the cost of more arthritis, migraine/headaches and 
vasculitis, which necessitates increased NSAID use; and 
while we lacked the data, we suspect that smoking would 
have a higher prevalence of infection or viral reactiva-
tion as well. Future research could investigate the scope 
for NAC supplementation to help prevent a rebounding 
effect of type I and II (IFN-γ) IFNs to aberrant levels in 
patients undergoing smoking cessation.18 70 Furthermore, 
use of type I or II IFN inhibitors in patients with SLE who 
smoke would likely be met with poorer treatment response 
and further increase the development and severity of viral 
infection or reactivation.70
Levels of IL- 1β are reported to be higher in patients with 
SLE relative to controls, especially with higher disease 
activity17 71 72; and lower levels of IL- 1β have been shown 
in well- managed,17 quiescent72 and now inversely associ-
ated with smoking in patients with SLE (age- adjusted and 
sex- adjusted model). Our data and others indicate that in 
patients with SLE, the by- products of smoking can reduce 
the levels of conventionally proinflammatory (TNF-α, 
IL- 12, IL- 17 and MIP- 1β) and anti- inflammatory (IL- 4) 
cytokines.27 73 While the depletion of these cytokines may 
not be significant enough to cause immune- mediated 
pathology, in the context of a reduced regulatory capacity 
of IL- 1β,30 this may increase the susceptibility of patients 
with SLE to infections, atherosclerosis, cardiovascular 
disease and cancer development.9 74–77 Thus, we speculate 
that smoking cessation may help normalise levels of IL- 1β 
in patients with SLE, which would help to inhibit unde-
sirable immune responses, possibly by increasing the 
Treg functionality via Th2 cytokines, and give protection 
against comorbidity.
The strength of this study is the availability of a large 
range of disease characteristics in all the patients, the 
inclusion of longitudinal organ damage data, and the 
adjustment for a range of cytokines involved in regu-
lating or exacerbating SLE. Some of the limitations 
of this study lie in the fact that our patients were all of 
Northern European descent and were mostly in a state 
of low disease activity, such that results cannot be extrap-
olated to cohorts with a different genetic or clinical 
makeup. The smoking exposure was captured prospec-
tively since SLE diagnosis (with the question ‘Have you 
smoked earlier or do you smoke daily?’) as well as at the 
research visit, meaning that the details of ex- smokers’ 
cigarette consumption, including ‘cigarettes smoked per 
day’, ‘years of continuous smoking’ and the ‘years since 
quit smoking’ to determine pack- years, was defined retro-
spectively by self- report. We lacked complete data on 
socioeconomic status and did not collect data on alcohol 
consumption, although we suspect these exposures 
would have minimal effect on the adjusted associations 
with cytokine levels. While we demonstrated an indepen-
dent association between smoking and IFN-γ, we did not 
have data on other type I IFNs, thus we cannot determine 
whether smoking directly influenced IFN-γ levels via type 
I IFNs or other cytokines, such as IL- 18, which can stim-
ulate the production of IFN-γ. Finally, our results were 
based on clinical and serological findings and, therefore, 
cannot confirm the cellular source or causation of effects 
of smoking on BAFF, IFN-γ and IL- 1β, for which further 
experimental studies will be needed.
CONCLUSION
Smoking independently associated with increased serum 
BAFF and decreased IFN-γ in patients with SLE. Smoking 
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included mucocutaneous features, arthritis, migraine/
lupus headaches and secondary Raynaud’s phenomenon, 
and necessitated increased use of NSAIDs. Smoking 
cessation should be encouraged in SLE with the aim 
to reduce systemic inflammation (BAFF and physician 
GDA), arthritis, vasospasticity, cutaneous features and 
NSAID requirement, while improving medication effi-
cacy (hydroxychloroquine) and innate immune compe-
tence (IFN-γ).
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